Prescription strength naprosyn

Naproxen Dosage Medically reviewed on March 14, 2017. When treating patients, especially at prescription strength naprosyn doses, sufficient increased clinical benefit should be observed to offset the potential for increased risk of adverse events. 2 weeks may be required to achieve therapeutic benefit.

The oral suspension is recommended due to flexible dose titration based on patient’s weight. The delayed release formulation has not been studied in patients less than 18 years. Moderate to severe renal dysfunction: Not recommended. Liver Dose Adjustments -Dose adjustments may be required in patients with liver dysfunction, however, no specific guidelines have been suggested.

Patients who have an abnormal liver test or who develop signs or symptoms of liver dysfunction should be evaluated for hepatic dysfunction. If liver disease develops or if systemic manifestations such as eosinophilia or rash occur, this drug should be discontinued. This risk may occur early in treatment and may increase with duration of use. These events can occur at any time during use and without warning symptoms. GI bleeding are at a greater risk for serious GI events. Safety and efficacy have not been established in patients younger than 2 years. Safety and efficacy have not been established in patients younger than 12 years.

Bookmark the permalink.